Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib
Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited managem...
Main Authors: | Karl R. Sorenson, Guilherme Piovezani Ramos, Jose Caetano Villasboas Bisneto, Katharine Price |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-08-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/479499 |
Similar Items
-
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
by: Laurence Booth, et al.
Published: (2019-07-01) -
Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
by: Sara Alkhezayem, et al.
Published: (2020-08-01) -
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2019-12-01) -
Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma
by: Tsuyoshi Sato, et al.
Published: (2021-03-01) -
Salivary duct carcinoma of the palate
by: Ponniah I, et al.
Published: (2005-01-01)